INTRODUCTION
Circulating soluble immune complexes and hypocomplementemia are associated with several clinical disorders. These include systemic lupus erythematosus, serum sickness reactions, scleroderma, Sjogren syndrome, mixed cryoglobulinemia, and Australia antigenemia. We have observed hypocomplementemia in 10% of sera tested from 6 Received for publication 14 June 1976 and in revised form 1 February 1977. potential significance in the understanding of the immune response to tumor antigens. One patient with chronic lymphocytic leukemia (CLL),1 hypocomplementemia, and cryoglobulinemia was studied in greater detail. Of special interest in this patient was the presence of high levels of antilymphocyte antibodies which were cold reactive and could be detected by both C-dependent cytotoxicity and indirect immunofluorescence. Free lymphocyte surface antigen was also demonstrated by gel diffusion with specific rabbit antilymphocyte antiserum. Sucrose density gradient ultracentrifugation at low pH (3.5) demonstrated that the antibody was 19S (1) .
The existence of circulating immune complexes in sera of cancer patients has recently been reported by us (2) (3) (4) and by Theofilopoulos et al. (5) . These investigators used the Raji cell radioimmune assay. In our studies we showed that sera of patients with low Clq levels (<10 ,ug/ml) determined by the Mancini technique (normal values [17] [18] [19] [20] [21] [22] [23] ,ug/ml) were strongly positive by the precipitation test described by Agnello et al. (6) . These sera with low Clq levels also inhibited the uptake of '25I-Clq by the Clq deviation test described by Sobel et al. (7) . In the present study we have (a) investigated the presence of immune complexes in sera of a large number of patients with various forms of malignancies; (b) compared the levels of total hemolytic complement (C) and C components (Clq, C3) with detectable immune complexes; (c) isolated the immune complexes by sucrose density gradient ultracentrifugation ' Abbreviations used in this paper: AHG, aggregated human gamma globulin; BCG, Calmette-Gu6rin bacillus; C, total hemolytic complement; Clq, INH%, inhibition of 125I-Clq uptake; CH5, serum dilution at which 50%o of the indicator erythrocytes are hemolyzed; CLL, chronic lymphocytic leukemia; DTT 
METHODS
Patient sera. Blood for complement studies and detection of immune complexes was obtained from patients at Memorial Hospital, New York with various forms of malignancies. The patients in this study in general were from the Outpatient Clinic or had been admitted to Memorial Hospital for surgery. The blood samples from the latter group of patients were drawn just before surgery and in general these patients were free of infections or fever. Studies of patients who had been treated will be presented with the Results. Blood samples were delivered on ice from the clinics and wards, kept at 4°C for 2-3 h, clarified by centrifugation, aliquoted, and kept at -80°C. Our experience demonstrates that it is critical that these samples be used for determination of immune complexes within 2 wk and that they not be thawed at intervals. (10) . The aggregation of IgG was carried out according to previously described methods (11 (14) . Total (Fig. 1) . Immune complexes were detected in sera of a high number of patients (Table I) . The presence and amount of complexes did not appear to be specific for a particular malignancy (Fig. 2) . However the amount of immune complexes was widely scattered. In several cases the levels of immune complexes were as high as those seen in sera of 10 patients studied with active systemic lupus erythematosus.
Comparison of serum levels of C, Clq, and C3 with the amount of circulating immune complexes in sera ofcancer patients. A comparative study oftotal hemolytic serum dilution at which 50% of the indicator erythrocytes are hemolyzed (CH50), Clq, C3, and the amount of circulating immune complexes was made from sera of 459 cancer patients (Table II) . As shown in the table, the mean values of C, Clq, and C3 in malignant sera were higher than normal. The correlations of C, Clq, and C3 with immune complexes are shown in Table III , and the results fall within five ranges (.2 SD, -1 SD, normal, <1 SD, and s2 SD). The percentage of sera with elevated levels of immune complexes (> 12 ,ug/ml) and the mean values of immune complexes in each group are presented. 453 sera were tested for total CH50, 440 were tested for Clq levels, and 446 were tested for C3 levels. The values determined were compared with levels of immune complexes. As shown in the Table, 44-57% of sera with elevated levels (2 + 1 SD or 2 + 2 SD) of all three components or with levels below -1 SD and within the normal range had high levels of immune complexes. 63-77% of sera with reduced levels of total C, C3, and Clq, particularly with levels Comparative studies on the amount of complexes associated with changes in C levels were also carried out whenever possible in serial samples of patients. It was seen that fluctuations of complexes occurred which correlated with changes in C levels. Two examples are presented (Fig. 3) . As seen in the serum of patient G. M., the amount of complexes decreased dramatically on the 3rd day from 93 to 19% (210 jig eq AHG/ml to 11 IL eq AHG/ml) with a concomitant increase of Clq levels from 15 ,ug N/ml to 22 ,ug N/ml. On the 49th day the levels of immune complexes were again elevated with significant decreases of C3 and total C levels. With patient N. K. (Fig.  3 ) the levels of immune complexes were found to be increased on the 22nd day (from 4 ug eq AHG/ ml to 40 ,tg eq AHG/ml) with a decrease of C3 and total hemolytic levels, but when measured on the 83rd day, the increased levels of immune complexes correlated with decreased levels of Clq only. These data indicate that increased levels of immune complexes in some instances cause a decrease in levels of C and of C components. These observations are consistent with our findings that although in some instances elevated levels of immune Levin et al. (13) for the presence of endotoxin, with a Limulus lysate with extremely high sensitivity to endotoxin (range> 0.04 ng/ml). Positive (Fig. 6 ). Although it is beyond the scope of this paper to identify the type of antibody present in the isolated complexes in various cancer sera studied, we were however able to show that antibody was present by the following experiment. Sera containing high levels of immune complexes were subjected to sucrose density gradient ultracentrifugation at pH 3.5. The fractions (>19S) that inhibited the uptake of '251-Clq by EA were pooled, reduced, and alkylated and then retested by the Clq DT. As seen in Table IV , the inhibition of uptake of '251-Clq in the treated sample decreased. This decrease was dependent upon the amount of reducing agent used.
Changes in levels of circulating immune complexes after treatment. During the course of our studies we were able to investigate serial serum samples of four melanoma patients undergoing therapy. The therapy was as follows. Tumor cells were removed from the patient and gently minced in RPMI-1640 medium (Grand Island Biological Co., Grand Island, N. Y.). The cells were irradiated to 10,000 R, mixed with Calmette-Guerin bacillus (BCG) (supplied by Research Foundation, Chicago, Ill.), and injected intradermally, usually every 2-3 wk, until the supply was exhausted. Blood was drawn periodically for C studies. As shown in Fig. 7 , in one patient (M. C.) there was a consistent and dramatic drop of levels of immune complexes concomitant with a drop of Clq levels 7-9 days after treatment. This was observed on two separate occasions. This drop was most marked on the 49th day (19.5-6 .0,ug eq/ml AHG) and on the 111th day (74-15% ,ug eq/ml AHG) with a concomitant increase of Clq from 20.5 to 26.5 ,ug N/ml and 23.5 to 31 ug N/ml, respectively. These are significant changes and do not reflect day-to-day errors. The levels of immune complexes and Clq increased 9-10 days after the combined tumor cell BCG therapy. A similar depression of immune complexes was also observed in three other patients (Figs. not presented) . However, the correlation between immune complexes and Clq was not always as clear as described for patient The study of this patient was extended to include other cancer patients. We showed that although 10% of the patients were hypocomplementemic, over 50% of the patients' sera had circulating immune complexes when tested by the Clq DT (2) . The quantity of complexes was sometimes as great as that detected in patients with systemic lupus erythematosus. DNA and endotoxin, substances known to interfere in the Clq DT, were negligible in sera of 50 cancer patients tested with high circulating immune complexes. (7), patients with Dengue hemorrhagic fever were characterized according to severity of disease into Grades I-IV. Sera from patients with disease Grade IV exhibited the highest degree of Clq deviation, and those from patients with Grade 1, the lowest. These data suggest that immune complexes in sera of these patients are pathogenically significant.
Sucrose density gradient ultracentrifugation at different pH values was used to analyze some of the immune complexes. At pH 7.2 higher levels of 125I-Clq inhibiting substances were present in the pellet of patient serum than in the pellet from normal serum. At pH 3.5 the immune complexes from the patient's serum sedimented at a region 19S. This was not observed with normal serum. These data suggest to us that complexes which before centrifugation were of heavy molecular substances gradually dissociated at low pH to a lighter molecular size. Reduction and alkylation of these isolated complexes showed that with increasing amount of reducing agents added, the 1251_ Clq inhibition decreased suggesting that antibody was present in these complexes.
Additional evidence for the presence of circulating immune complexes in malignancy has been recently reported by other investigators (5, 19, 20) with different techniques. The occurrence of immune complexes in a high number of cancer patients could be of potential significance in the understanding ofthe immune response to tumor antigens, particularly in the light of observations by several investigators in experimental animals. It has been shown that immunity can be induced against many experimentally induced animal tumor antigens when transplanted into syngeneic hosts (21) (22) (23) . This immune response may have a diminished effect in the rejection of the tumor transplant by the presence of circulating humoral factors, i.e., blocking factors. It has been suggested that the blocking factors can be antibody (24) (25) (26) but there is greater evidence that blocking is mediated by immune complexes (24, 27, 28) . Whether the circulating antigen-antibody complexes in sera of cancer patients have blocking effects will be elucidated by further studies.
